The laboratory has also all of the
technologies required to produce recombinant bacteria expressing
vaccine antigens to be used as non-pathogenic
vaccine vectors.
The program will be packed with papers on biochromatography, downstream processing, QbD, monoclonal antibodies, plasmids, enzymes,
vaccines, viral
vectors for gene delivery, VLPs, and other biopharmaceuticals, chiral molecules, SFC, fine chemicals, peptides, proteins, oligonucleotides, APIs, natural products, batch, multi-column and continuous SMB processes, column
technology and equipment, monoliths, new and improved stationary phases, membrane chromatography, regulatory aspects, and more!
Research & Development IAVI worked with the Japanese biotech company DNAVEC, based in Tsukuba City, to jointly develop an AIDS
vaccine candidate based on its novel Sendai
vector technology.